Partners

Co-founded by Institut national de la sante et de la recherche medicale (INSERM), Institut Carnot and Assistance publique-Hopitaux de Paris (APHP), Institut Imagine is the first European center for research, care and teaching on genetic diseases. With the mission of understanding and finding a cure for these diseases, the Institute brings together 1000 of the best clinicians, researchers and healthcare personnel in an architecture that creates synergies between teams. It is this expertise and the proximity with patients that allows Imagine to make discoveries for patients. The 8,000 genetic diseases that have been identified affect 35 million patients in Europe, and almost 3 million in France, where 30,000 new cases are diagnosed each year. Nearly 50% of children leave consultation without a genetic diagnosis and 85% of genetic diseases have no cure. Faced with this major public health issue, the challenge is doubled: to diagnose and find a cure.

IRCCS Ospedale San Raffaele is a university and research hospital established in 1971, capable of offering specialised care for the most complex medical conditions. In 1972, the hospital was officially recognised as a research hospital (Istituto di Ricovero e Cura a Carattere Scientifico, IRCCS), and in 2012 it became part of Gruppo San Donato. With over 60 clinical units and 100 research laboratories, IRCCS Ospedale San Raffaele combines both clinical and scientific activities through a translational approach whereby discoveries made in the laboratory inform clinical practice and research is driven by clinical needs.

With roughly 14,000 employees, the Medical Center – University of Freiburg is among the largest university medical centers in Germany. Around 1,700 doctors and more than 3,900 nurses provide care to more than 90,000 inpatients and around 820,000 outpatients per year. The Medical Center – University of Freiburg engages in research, teaching, and healthcare as its core responsibilities, always with the goal of offering its patients treatment informed by the latest scientific findings – today and in the future.

Bar-Ilan University, founded in 1955, is one of Israel’s leading institutions of higher education, with nine faculties that are active partners in the country’s national science and technology initiatives.  The university’s milestone achievements in the sciences and humanities and all fields of human endeavor have made an indelible imprint on the landscape of the State of Israel.

A microcosm of Israeli society, Bar-Ilan has a diverse student body of close to 19,000. Serving as a bridge between Israel’s diverse sectors, Bar-Ilan University, with its multicultural campus environment, provides a singular forum for free thought and open discussion.

Inserm is a public scientific and technological institute which operates under the joint authority of the French Ministries of Health and Research. The institute is dedicated to biomedical research and human health, and is involved in the entire range of activities from the laboratory to the patient’s bedside. It also partners with the most prestigious research institutions in the world that are committed to scientific challenges and progress in these fields.

Freedom and individual responsibility, entrepreneurial spirit and open-mindedness: ETH Zurich stands on a bedrock of true Swiss values. Our university for science and technology dates back to the year 1855, when the founders of modern-day Switzerland created it as a centre of innovation and knowledge. At ETH Zurich, students discover an ideal environment for independent thinking, researchers a climate which inspires top performance. Situated in the heart of Europe, yet forging connections all over the world, ETH Zurich is pioneering effective solutions to the global challenges of today and tomorrow.

AstraZeneca is a British-Swedish multinational pharmaceutical and biotechnology company. They are focused on creating genuinely innovative medicines and improving access to them. In this way, Astrazeneca deliver the greatest benefit to patients, healthcare systems and societies globally. Astrazeneca’s business is organised to deliver innovation tools through three strategic priorities: oncology, rare disease and biopharamceuticals.

EATRIS, the European Research Infrastructure for Translational Medicine, is one of the leading permanent European infrastructures for translational sciences. The infrastructure provides access to excellent academic expertise and facilities across Europe to accelerate early medicine development and advance promising medical research for the benefit of patients. EATRIS is active in the preclinical and very early clinical phases of the development of medicines, diagnostics and vaccines. Central to its mission is to support the development of innovative next generation therapies including cell and gene therapy products.

EATRIS is a non-profit organisation based in Amsterdam, NL, supported by 14 European countries and representing 127 leading academic and non-profit biomedical research institutions. EATRIS collaborates with a wide range of users and stakeholders, including academia, SMEs and large pharma/biotech, as well as patient organisations and research funding organisations.